Ixprim

Tramadol Hydrochloride, the active ingredient in Ixprim, is an opioid analgesic presented as a 75 mg/650 mg oral tablet for oral use. It treats moderate to severe acute pain, post‑operative pain and musculoskeletal pain in adult patients.

GNH USA supplies Ixprim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Its distribution network ensures timely delivery and compliance with regulatory requirements across multiple regions.

Ixprim, a combined opioid and non‑opioid analgesic, is indicated for several acute pain conditions. - Moderate to severe acute pain: provides rapid relief of pain intensity, improves patient comfort, and enhances functional ability during acute episodes. - Post‑operative pain: assists in controlling pain after surgical procedures, supports early mobilization, and contributes to faster postoperative recovery. - Musculoskeletal pain: alleviates pain linked to injuries, strains, or inflammatory conditions of muscles, joints, and connective tissue, aiding daily activities.

Ixprim may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea: a feeling of sickness that may lead to vomiting. - Dizziness: light‑headedness or loss of balance, especially when standing quickly. - Constipation: reduced bowel movements and difficulty passing stool. - Headache: mild to moderate pain in the head or temples.

Serious or Rare Side Effects: - Seizures: sudden uncontrolled electrical activity in the brain, potentially leading to convulsions. - Respiratory depression: slowed or shallow breathing that can become life‑threatening. - Serotonin syndrome: a potentially fatal condition characterized by agitation, hyperthermia, tremor, and autonomic instability.

When prescribing Ixprim, clinicians should observe several precautionary measures to ensure safe use. - Assess pain severity: confirm that the pain level justifies combined opioid/non‑opioid therapy. - Evaluate respiratory function: avoid use in patients with severe respiratory depression or compromised ventilation. - Review hepatic status: adjust use in patients with significant liver impairment. - Monitor for dependence: be vigilant for signs of opioid misuse or tolerance development. - Caution with CNS depressants: limit concurrent use of alcohol, benzodiazepines or other sedatives. - Store at below 25°C: keep tablets in the original packaging, protect from moisture and direct sunlight.

Ixprim can interact with other medicines, and some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate serotonin syndrome. - SSRIs or SNRIs: increase risk of serotonin syndrome when combined with tramadol. - CNS depressants: additive sedation and respiratory depression with benzodiazepines, barbiturates or alcohol. - CYP2D6 inhibitors: reduce tramadol activation, potentially decreasing analgesic effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may lower plasma concentrations of both components, reducing efficacy. - NSAIDs: combined use can raise the risk of gastrointestinal bleeding. - Antihypertensives: tramadol may enhance hypotensive effects, requiring blood pressure monitoring.